Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (2085)	10/4/1997 12:27:00 AM
From: jay silberman	of 6136

From Briefing.com (posted 1:35 PM) AGOURON PHARMACEUTICALS INC. (AGPH) 47 1/16 +2 13/16. Shares of drug developer are getting a lift today from a ratings upgrade from BT Alex. Brown after the company announced yesterday that it was joining forces with British organizations to develop new anti-cancer drugs. This morning, BT Alex. Brown upped its rating on the stock to a "strong buy" from a "buy" rating, reversing yesterday's trend when the stock lost $2 7/8. The stock has been on a roller coaster ride the past few weeks as opinion from experts vary on the company's Viracept protease inhibitor AIDS drug. While a month ago, the drug was being hailed as a savior when used with other drugs to fight the HIV virus, in recent weeks questions have arisen suggesting that the drug is not as potent as once claimed. And given that this is the company's sole revenue generator at the moment, the stock has traded with a downward bias since reaching an all time high of $56 1/2 in mid-September. Certainly, this issue is not for the weak of heart, but there is still promise that Viracept when used in the right combination can still prove to be helpful in combating the AIDS virus.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next